AI in Neurology Market: Drug Development, Risk Prediction, and Enterprise Readiness
Beyond diagnostics, the AI in neurology market is expanding into research, treatment planning, and patient monitoring. Polaris Market Research estimates the market at USD 759.2 million in 2025, projected to reach USD 5,619.9 million by 2034 at a CAGR of 25.0% during 2026–2034. North America was the largest market in 2025 with a 40.63% revenue share. Growth is driven by the increasing prevalence of neurological disorders and rising demand for advanced diagnostic tools, and aging populations are driving the need for early detection and continuous monitoring systems. Favorable regulations and investment in healthcare infrastructure are also boosting adoption.
AI-Driven Drug Discovery Opens New Pathways
AI-driven drug discovery is facilitating rapid identification of potential molecules for treating neurological conditions. In April 2026, Brenig Therapeutics introduced a new approach to drug discovery that incorporated physics-based structural biology and machine learning in its AI model.
The drug discovery segment is projected to grow at a CAGR of 25.4%, due to rising use of AI biomarker discovery platforms for identifying novel CNS therapeutics. AI models are accelerating target identification, biomarker discovery, and clinical trial optimization.
Pharma Companies Increase Investment
The pharma companies end-user segment is projected to grow at the fastest rate during the forecast period, driven by investment in AI for drug development and clinical research. These organizations are using AI platforms to streamline research processes and accelerate the development of neurological therapies. The pharmaceutical industry uses AI to speed up drug development, supported by growing access to healthcare data and advances in computing ability.
Investment trends point the same way. Neurology-focused AI companies are receiving substantial investment, pharmaceutical organizations are partnering with AI businesses to expedite drug discovery and testing, and M&A activity is becoming more common as large healthcare technology organizations acquire AI capabilities through niche acquisitions.
Predictive Analytics for Risk and Planning
Predictive analytics shows high adoption, with fast-growing use in early risk detection, disease progression tracking, and treatment planning. The machine learning segment is expected to grow at a CAGR of 25.6%, due to its expanding role in predictive analytics, patient monitoring, and decision support. Machine learning algorithms are also used in neurosurgery for risk assessment, surgical planning, and outcome prediction. Natural language processing shows medium adoption, with emerging use in clinical documentation, patient data analysis, and decision support.
Clinical Validation and Hospital Integration
Competition in the market is influenced by the precision of algorithms, clinical validation, hospital integration, and regulatory adherence. Hospitals accounted for 54.6% of the market in 2025, supported by advanced imaging infrastructure that enables AI tools to be embedded in diagnosis, treatment planning, and patient monitoring.
The report notes strong results from neurology AI applications, including shortened diagnostic periods, increased precision in imaging studies, and early disease diagnosis. Healthcare organizations have reported financial gains from streamlined processes, less human involvement, and improved resource allocation, and better medical results are decreasing future treatment expenses. In the rest of the world, the Middle East is moving toward smarter hospitals using AI, while Latin America is at an initial stage of adoption.
𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐓𝐡𝐞 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞 :
https://www.polarismarketresearch.com/industry-analysis/ai-in-neurology-market
Cost and Regulatory Constraints
Implementation requires significant capital expenditure on infrastructure, data processing, and validation procedures, and healthcare regulations and data security guidelines add complexity. These factors limit deployment in smaller healthcare facilities and developing nations. Europe is shaped by strict regulatory compliance and a strong focus on AI ethics, while Asia Pacific is growing at a CAGR of 25.6% on the back of government investment.
Key Players
The industry is moderately concentrated. Major players include Activ Surgical, Airamed GmbH, Brainomix Limited, BrainQ Technologies Ltd., Canon Inc., GE Healthcare, Koninklijke Philips N.V., Medtronic Plc, Neosoma Inc., Neuralink Corporation, Neurox, NVIDIA Corporation, Qure.AI, Siemens Healthineers AG, and Viz.ai Inc.
Across research, risk prediction, and clinical deployment, the AI in neurology market depends on both technical precision and operational readiness.
Conclusion
The AI in neurology market is gaining traction as healthcare providers increasingly adopt advanced technologies to improve neurological diagnosis and treatment. Artificial intelligence is helping clinicians analyze medical images, identify disease patterns, and support the management of conditions such as Alzheimer's disease, epilepsy, and Parkinson's disease. Growing neurological disease prevalence and advancements in machine learning are creating significant opportunities for market expansion. Integration of AI tools into clinical workflows may also improve diagnostic efficiency and personalized patient care. However, data privacy concerns, algorithm reliability, and regulatory requirements remain important challenges. The market is expected to advance as clinical validation and healthcare technology integration continue to improve.
More Trending Latest Reports By Polaris Market Research:
Europe Pneumococcal Vaccine Market
In-Vehicle Infotainment Market
Cell & Gene Therapy Bioanalytical Testing Services Market
Europe Pneumococcal Vaccine Market
Increasing Prevalence and New Product Launches to Propel Growth